Nsaids

Risk of renal dysfunction and acute renal failure, especially in elderly, volume-depleted, or renal-impaired patients. Antihypertensive effect may be attenuated.

In elderly, volume-depleted, or renally impaired patients, coadministration may result in deterioration of renal function including possible acute renal failure. NSAIDs may attenuate antihypertensive effect. Monitor renal function.

May result in deterioration of renal function, acute renal failure, and attenuation of antihypertensive effect of olmesartan. Monitor renal function periodically.

Chronic NSAID use increases bleeding risk when combined with apixaban.

Concurrent use of aspirin with other NSAIDs may increase bleeding risk or decrease renal function.

Concurrent use with aspirin may increase bleeding risk or lead to decreased renal function.

Concurrent use with aspirin may increase bleeding risk or lead to decreased renal function.

NSAIDs increase risk of renal dysfunction and acute renal failure when combined with azilsartan, particularly in elderly, volume-depleted, or renally impaired patients. NSAIDs also attenuate antihypertensive effect.

Increased risk of renal impairment, acute renal failure, and loss of antihypertensive efficacy, especially in elderly, volume-depleted, or renal-compromised patients.

May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients.

May result in deterioration of renal function, possible acute renal failure, and attenuation of antihypertensive effect, especially in elderly, volume-depleted, or renally compromised patients.

May result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensive effect. Risk increased in elderly, volume-depleted, or renal-compromised patients.

NSAIDs may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. NSAIDs may also attenuate the antihypertensive effect.

Coadministration in elderly, volume-depleted, or renal-compromised patients may result in deterioration of renal function including acute renal failure. NSAIDs may attenuate antihypertensive effect.

Concurrent use of NSAIDs with citalopram may potentiate the risk of upper gastrointestinal bleeding due to interference with serotonin reuptake and platelet hemostasis.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis and serotonin reuptake inhibition.

Coadministration increases risk of gastrointestinal bleeding.

Increases risk of gastrointestinal bleeding when coadministered with clopidogrel.

Concomitant use increases risk of bleeding. Clinical studies showed increased rates of clinically relevant bleeding; careful monitoring recommended.

May result in deterioration of renal function, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. NSAIDs may also diminish antihypertensive effect.

Co-administration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Monitor renal function periodically.

Chronic NSAID use increases the risk of bleeding when coadministered.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to interference with hemostasis.

Concurrent use with fluoxetine may potentiate risk of upper gastrointestinal bleeding due to fluoxetine's effect on platelet serotonin.

Concurrent use with NSAIDs may potentiate upper gastrointestinal bleeding risk due to fluoxetine's effect on platelet serotonin.

In elderly, volume-depleted, or renal-impaired patients, may result in deterioration of renal function including acute renal failure. May attenuate antihypertensive effect.

Coadministration may result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

NSAIDs can reduce diuretic and natriuretic effects, and may lead to renal impairment and reduced antihypertensive effect. Monitor renal function periodically.

May result in deterioration of renal function including possible acute renal failure, especially in elderly or volume-depleted patients. Attenuates antihypertensive effect. Monitor renal function periodically.

NSAIDs may result in deterioration of renal function, including possible acute renal failure, in elderly patients, volume-depleted patients, or those with compromised renal function. NSAIDs may also attenuate the antihypertensive effect.

May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renal-impaired patients. Antihypertensive effect may be attenuated.

May result in deterioration of renal function, including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. Antihypertensive effect may be attenuated.

May result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

Increased risk of nephrotoxicity with concurrent use; monitor renal function and mesalamine-related adverse reactions.

High-dose concurrent use reported to elevate and prolong serum methotrexate levels, causing deaths from severe hematologic and gastrointestinal toxicity. Lower doses require caution.

NSAIDs may result in deterioration of renal function, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

Concomitant administration with ofloxacin may increase risk of CNS stimulation and convulsive seizures.

Co-administration may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renally impaired patients. Antihypertensive effect may be attenuated.

May lead to increased risk of renal impairment, loss of antihypertensive effect, and deterioration of renal function including possible acute renal failure.

May lead to increased risk of renal impairment, loss of antihypertensive effect, and deterioration of renal function including possible acute renal failure in elderly or volume-depleted patients.

Reduced diuretic, natriuretic and antihypertensive effects; increased risk of renal toxicity and acute renal failure, especially in elderly or volume-depleted patients.

Co-administration may result in deterioration of renal function, including possible acute renal failure, and may attenuate antihypertensive effects. Monitor renal function and blood pressure.

Bleeding has been reported in patients treated with pentoxifylline with or without concomitant NSAIDs.

May lead to increased risk of renal impairment and loss of antihypertensive effect.

Monitor for hyperkalemia. NSAIDs may produce potassium retention by reducing renal prostaglandin E synthesis and impairing the renin-angiotensin system.

Monitor for hyperkalemia. NSAIDs reduce renal prostaglandin E synthesis and impair the renin-angiotensin system.

In elderly, volume-depleted, or renal-compromised patients, NSAIDs with ACE inhibitors may cause renal function deterioration including acute renal failure. Antihypertensive effect may be attenuated.

May result in deterioration of renal function, acute renal failure, and attenuation of antihypertensive effect, especially in elderly, volume-depleted, or renal-compromised patients.

May result in worsening renal function, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients.

NSAIDs with telmisartan may cause renal function deterioration, including acute renal failure, especially in elderly, volume-depleted, or renally compromised patients. Antihypertensive effect may be attenuated.

May result in deterioration of renal function including acute renal failure in elderly, volume-depleted, or renally compromised patients. Attenuates antihypertensive effect and reduces diuretic efficacy.

Increased risk of renal impairment and loss of antihypertensive effect, especially in elderly, volume-depleted, or renally compromised patients. May result in acute renal failure.

Co-administration with trandolapril may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renal-impaired patients.

Concomitant use with corticosteroids increases risk of gastrointestinal side effects.

May result in deterioration of renal function including acute renal failure, especially in elderly or volume-depleted patients. Antihypertensive effect may be attenuated. Monitor renal function periodically.

NSAIDs with valsartan may result in deterioration of renal function including possible acute renal failure, especially in elderly, volume-depleted, or renal-compromised patients. Antihypertensive effect may be attenuated.

Increased risk of upper gastrointestinal bleeding due to impaired serotonin reuptake affecting platelet hemostasis.

Concurrent use may increase risk of renal reactions and nephrotoxicity. Monitor for changes in renal function and mesalamine-related adverse reactions.

NSAIDs may reduce the diuretic, natriuretic, and antihypertensive effect of CAROSPIR. Monitor closely for desired diuretic effect.

May increase risk of water intoxication with hyponatremia; concomitant administration should be performed with caution.

May increase risk of water intoxication with hyponatremia. Monitor serum sodium more frequently.

Concomitant use may potentiate risk of bleeding due to effect on serotonin release by platelets. Closely monitor for bleeding.

Concomitant administration may result in increased NSAID adverse effects due to systemic exposure of diclofenac.

May increase serum potassium concentration when used with drospirenone.

NSAIDs may increase serum potassium in women taking drospirenone, more pronounced in diabetic women.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to effects on serotonin-mediated platelet function.

Concurrent use may potentiate risk of upper gastrointestinal bleeding due to serotonin reuptake inhibition effects on platelet function.

High-dose or multiple NSAIDs coadministration may increase serum concentrations of emtricitabine, tenofovir, and/or NSAIDs due to competition for renal tubular secretion.

May reduce antihypertensive effect and result in severe hyperkalemia with impaired renal function. Monitor blood pressure and serum potassium levels when used concomitantly.

Use with caution; concurrent use may potentiate the risk of upper gastrointestinal bleeding.

May increase the glucose-lowering effect of glimepiride due to high protein binding, increasing susceptibility to hypoglycemia.

Antiplatelet drugs that may potentiate bleeding risk when used with levomilnacipran. Closely monitor for bleeding.

NSAIDs decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations.

NSAIDs decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations. Frequent monitoring and dosage adjustment recommended.

NSAIDs decrease renal blood flow, resulting in decreased renal clearance and increased serum lithium concentrations.

May potentiate risk of bleeding when used with olanzapine and fluoxetine.

May produce unfavorable interactions with potassium supplements, risk of hyperkalemia.

Chronic coadministration may increase the risk of bleeding.

Concomitant use with NSAIDs increases the risk of gastrointestinal side effects.

Concomitant use increases risk of gastrointestinal side effects.

NSAID users developed upper gastrointestinal adverse reactions at 18% vs 13% in non-users taking Atelvia, suggesting increased GI risk with concurrent use.

NSAIDs may reduce the diuretic, natriuretic, and antihypertensive effect of spironolactone. Monitor closely for desired diuretic effect.

NSAIDs may increase risk of renal impairment and loss of antihypertensive effect, particularly in elderly, volume-depleted, or renally compromised patients. Monitor renal function periodically.